Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Health Care Conference 2026 on May 12, 2026 at 11:20 a.m. PT (2:20 p.m. ET) in Las Vegas. The presentation will be webcast live and available on the company's Investors site.
According to the company, a replay will be posted about one hour after the event and archived on the website for approximately one month. Neurocrine describes its business focus, FDA-approved products across neurology and endocrine indications, and a mid- to late-stage clinical pipeline.
Neurocrine Biosciences (NASDAQ: NBIX) released survey findings on May 4, 2026 showing substantial employment impacts from tardive dyskinesia (TD). About 1 in 5 surveyed working adults with TD quit their job due to symptoms and respondents missed an average of 8 hours of work or school per week prior to treatment.
The online Ipsos survey included 70 adults diagnosed with TD and 30 caregivers; employment analyses used a 59-person respondent base. The release highlights low treatment rates with VMAT2 inhibitors and high levels of undiagnosed TD.
Neurocrine Biosciences (Nasdaq: NBIX) initiated a Phase 1 first-in-human study of NBIP-'2118, a CRF2 peptide agonist for obesity, on May 4, 2026. The trial will test single ascending doses versus placebo in healthy-weight, overweight, and obese adults, with initial data expected in 2027.
NBIP-'2118 is designed for once-weekly subcutaneous dosing; preclinical data showed fat loss with preservation or increase of lean mass. Neurocrine is developing complementary programs including NBIP-'1968 (GLP-1/GIP/glucagon triple agonist) and CRF2-incretin conjugates.
Neurocrine Biosciences (Nasdaq: NBIX) presented two-year data from the Phase 3 CAHtalyst Pediatric study showing durable hormone control and reduced glucocorticoid exposure with CRENESSITY (crinecerfont) in children and adolescents with classic congenital adrenal hyperplasia (CAH).
Key results: sustained ACTH and 17‑OHP reductions to Month 24, mean GC dose fell from 16.4 to 13.2 mg/m²/day, BMI SDS and HOMA‑IR improved in relevant baseline subgroups, and >80% study retention with no new safety signals.
Neurocrine Biosciences (NASDAQ: NBIX) announced publication in The Journal of Clinical Psychiatry establishing a minimal clinically important difference (MCID) of four points on the Tardive Dyskinesia Impact Scale (TDIS).
The research shows TDIS captures patient‑reported physical, social and emotional improvements with INGREZZA (valbenazine) across KINECT 3, KINECT 4 and KINECT-PRO clinical studies, providing a clearer threshold to interpret meaningful treatment benefit.
Neurocrine Biosciences (Nasdaq: NBIX) presented two-year Phase 3 CAHtalyst Adult data showing sustained glucocorticoid (GC) dose reductions with CRENESSITY (crinecerfont) in adults with classic congenital adrenal hyperplasia.
At Month 24, 69% (103/149) reached physiologic GC dosing (≤11 mg/m2/day HCe); mean daily dose fell from 17.6 to 10.6 mg/m2/day HCe (−38%). Study retention exceeded 80% at two years with no new safety signals reported.
Neurocrine Biosciences (Nasdaq: NBIX) scheduled its Q1 2026 financial results release and conference call for May 5, 2026. The press release will be at 1:00 p.m. PT / 4:00 p.m. ET and the live conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Dial-in numbers and a webcast are provided; a replay will be available about one hour after the event and archived for approximately one month on the company's investors website.
Neurocrine Biosciences (Nasdaq: NBIX) presented a retrospective real-world claims analysis showing greater treatment persistence with INGREZZA (valbenazine) versus AUSTEDO XR (deutetrabenazine) in adults with tardive dyskinesia.
In matched cohorts (n=1,494 each) over six months, INGREZZA had 55.6% persistence vs 48.1% for AUSTEDO XR (p<0.0001); switching rates were 7.7% vs 11.2% (p=0.0012); median time to discontinuation was >180 days vs 129 days.
Neurocrine (Nasdaq: NBIX) will acquire Soleno for $53.00 per share, valuing the deal at approximately $2.9 billion. The acquisition adds VYKAT XR, which generated $190 million in 2025 revenue (including $92 million in Q4 2025), and its IP expected into the mid-2040s. Post-close, Neurocrine's marketed portfolio will include INGREZZA ($2.51 billion 2025 revenue), CRENESSITY ($301 million 2025 revenue), and VYKAT XR. The tender offer is subject to customary conditions and expected to close within 90 days. Neurocrine will fund the deal with cash on hand and a modest amount of pre-payable debt.
Neurocrine Biosciences (Nasdaq: NBIX) presented the first expert consensus recommendations for screening, diagnosis and treatment of tardive dyskinesia (TD) in long-term care on March 26, 2026. The multidisciplinary Delphi panel endorses routine AIMS screening, quarterly checks for residents on dopamine blockers, and use of VMAT2 inhibitors with tailored selection factors.
A post-hoc KINECT-PRO analysis in adults 65+ shows clinically meaningful patient-reported improvements with once-daily INGREZZA (valbenazine) at Week 24, and the company highlights formulation and dosing features relevant for long-term care residents.